Summary In a case-control study of 280 out of 426 consecutive patients with a recent diagnosis of nonHodgkin lymphoma (NHL) and 1827 control subjects, 53 (19%) and 230 (13%) respectively had received blood transfusions 1 year or more before the interview. Using an age-and sex-stratified analysis the odds ratio (OR) for transfusion was 1.74 (95% CI 1.24-2.44). ORs were also determined for transfusions received in the intervals 1 -5, 6 -15, 16-25 and > , Carli et al., 1994 , Cartwright et al., 1994 , National Board of Health and Welfare, 1995. The causes of this increase are unknown, and in an attempt to identify risk factors for NHL a case-control study has been initiated in the Southern Health Care Region of Sweden.
The incidence of non-Hodgkin lymphoma (NHL) is increasing quite rapidly in many populations, including Scandinavia (Coleman et al., 1993 , Carli et al., 1994 , Cartwright et al., 1994 , National Board of Health and Welfare, 1995 . The causes of this increase are unknown, and in an attempt to identify risk factors for NHL a case-control study has been initiated in the Southern Health Care Region of Sweden.
According to cohort studies of cancer morbidity in blood recipients, transfusions may be a risk factor for NHL. In a Swedish study (Blomberg et al., 1993) an excess of NHL was observed in previously transfused subjects, the standardised morbidity ratio being 4.09 (95% CI 1. 65-8.43 ). Cerhan et al. (1993) obtained information about past transfusions from women aged 55-69 years who were resident in Iowa and followed up for 5 years. For women who had ever received a blood transfusion the relative risk of NHL was 2.20 (95% CI 1. 35-3.58 ). Memon and Doll (1994) identified nearly 13 000 infants who received blood transfusions shortly after birth in England, Wales and Scotland and recorded the incidence of subsequent malignant tumours. The incidence of NHL at 15-49 years of age was about twice that expected, but the excess was not statistically significant.
Our ongoing case-control study offered an opportunity to further evaluate the relation between previous blood transfusions and the development of NHL. We report here on the association between transfusions and NHL. The relation between the time lapse since transfusion and the risk of lymphoma has also been studied. (Table I) . For transfusions received 6-15 years before diagnosis the OR was 2.83, 95% CI 1.60-4.99 (Table II) . The ratios for earlier or later transfusions were elevated but not statistically significant (Table II) .
Subjects and methods
Low-grade nodal lymphoma Among the patients for whom histological diagnosis and results of clinical staging were available, 82 had low-grade nodal lymphoma with or without disseminated disease and 18 (22%) of these had been transfused; OR for a transfusion history was 2.02, 95% CI 1.16-3.51 (Table I) .
In a small subgroup of 31 patients with lymphoma of B- (Table II). A total of 44 patients had low-grade lymphoma of follicle centre cell type (centrocytic, centroblastic/centrocytic) and five (11%) had a history of transfusion with a non-significant OR= 0.91, 95% CI 0.35-2.36 (Table I ). Seven other patients had unclassified low-grade lymphomas, of whom two had received transfusions.
Low-grade extranodal lymphoma Only eight patients presented with low-grade extranodal lymphoma as the sole initial manifestation and one of these (13%) had received a transfusion (Table I) . 
Discussion
The results of this case-control study indicate an increased risk of NHL for recipients of blood transfusions and are in line with conclusions from recent cohort studies (Blomberg et al., 1993; Cerhan et al., 1993) . For a subset of the patients, the histological type and results of staging procedures are known. Although the numbers of transfused patients were small in some clinical subgroups of NHL, the results suggest that a transfusion history may be particularly related to nodal B-CLL or immunocytoma and to extranodal highgrade lymphoma. The highest ORs were recorded for transfusions received 6-15 years before diagnosis. Because of the small number of patients studied in various intervals, the confidence intervals for the ORs are wide, so these data must be interpreted with caution. It was considered possible that the patients with a malignant disease might recall transfusions to a larger extent than control subjects. In the sarcoma patients the OR for transfusions was, however, about 1.0. It is therefore unlikely that recall bias is of great importance for the elevated ORs.
One patient with extranodal high-grade lymphoma in the caecal region was transfused because of anaemia 1 year before diganosis. We have therefore considered the possibility that lymphoproliferative disease might have prompted transfusion in other cases. Transfusions would then be particularly common in a period near diagnosis. In the interval 1-5 years before diagnosis the OR for transfusions was, however, lower than the OR for transfusions received 6-15 years before diagnosis. In the lymphoma groups significantly associated with a transfusion history, the reasons for transfusion were not unusual or related to any known condition with an increased risk of lymphoma. A similar pattern of reasons for transfusion was recorded in a previous study of blood recipients who showed an increase in NHL (Blomberg et al., 1993) . It is therefore unlikely that the elevated ORs for transfusion were due to the malignant lymphoma itself or to any predisposing disease.
Immunodeficiency, whether genetic, viral or iatrogenic, is a well-known risk factor for NHL. Homologous blood transfusions have some immunosuppressive effect (Fisher et al., 1980 , George and Morello, 1986 , Heiss et al., 1993 , although the mechanisms have not yet been elucidated (Bordin et al., 1994) . Lymphomas in transplanted patients under immunosuppressive treatment are generally of highgrade morphology and are often extranodal (Starzl et al., 1984) . This is also characteristic of AIDS-associated lymphomas in which immunosuppression is considered to be an important determinant of the increased risk (Beral et al., 1991) . The present results also raise the possibility that immunosuppression caused by transfusions may also increase the risk of high-grade extranodal lymphomas. However, lowgrade nodal lymphomas of B-CLL or immunocytoma type were also strongly related to a transfusion history. In posttransplant patients the incidence of NHL is related to the aggressiveness of the immunosuppressive regimen (Opelz and Henderson, 1993) . It is conceivable that the immunosuppressive effect of blood transfusions is transient and relatively weak compared with the post-transplantation situation. Although immune impairment may be a common determinant for increased risk of NHL in transplanted and transfused patients, the differences in duration and intensity of the immunosuppressive state may cause the partly dissimilar patterns of lymphoma presentation.
In kidney and heart transplant recipients undergoing immunosuppressive treatment the risk of NHL is 20-120 times higher than normal and is most pronounced during the first year after transplantation (Opelz and Henderson, 1993) . The far lower risk and the generally longer latency period for transfused patients may also be due to a relatively weak and transient immunosuppression in blood recipients.
Transmission in the transfused blood of some blood-borne oncogenic virus might also account for the association between transfusions and subsequent NHL. HIV infection would seem unlikely in the present material. In the past 3 years HIV tests have been included in the laboratory investigations of patients with a recent diagnosis of NHL at The factors responsible for the increasing incidence of NHL have not been established. In the search for aetiological factors it might be rewarding to study clinical subgroups rather than the whole heterogeneous group of NHL. Such an approach is supported by our results. A large effect of blood transfusions was observed only for NHL of B-CLL or immunocytoma type and high-grade extranodal lymphomas. For other, relatively large subgroups of NHL. i.e. high-grade nodal and low-grade follicle centre cell lymphomas. no relation to previous transfusions was detected.
